Market Cap | 74.50M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -64.19M | Forward P/E | -5.31 | EPS next Y | - | 50D Avg Chg | -4.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -11.00% |
Dividend | N/A | Price/Book | 0.64 | EPS next 5Y | - | 52W High Chg | -42.00% |
Recommedations | 3.00 | Quick Ratio | 59.65 | Shares Outstanding | 67.06M | 52W Low Chg | 25.00% |
Insider Own | 10.38% | ROA | -24.54% | Shares Float | 26.24M | Beta | -0.35 |
Inst Own | 77.67% | ROE | -38.35% | Shares Shorted/Prior | 1.15M/1.07M | Price | 2.76 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 27,470 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 9,457 | Change | -1.08% |
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
HC Wainwright & Co. | Neutral | Mar 8, 23 |
HC Wainwright & Co. | Neutral | Feb 10, 23 |
HC Wainwright & Co. | Buy | Oct 28, 22 |
SVB Leerink | Outperform | Aug 16, 22 |
SVB Leerink | Outperform | Jul 11, 22 |
Guggenheim | Neutral | Apr 26, 22 |
SVB Leerink | Outperform | Apr 26, 22 |
Guggenheim | Buy | Sep 7, 21 |
Stifel | Buy | Sep 7, 21 |